Avoro Capital Advisors LLC and portfolio manager Behzad Aghazadeh filed Amendment No. 2 to Schedule 13G with the SEC on November 16, 2026, disclosing a combined beneficial ownership position in Vera Therapeutics, Inc. (NASDAQ:VERA) Class A Common Stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Both reporting persons each hold 5,635,000 shares of Vera Therapeutics Class A Common Stock.
  • Percent of class: The 5,635,000 shares represent 7.82% of the class, based on 72,063,335 shares outstanding as of July 29, 2026.
  • Sole voting and dispositive power: Both Avoro Capital Advisors LLC and Behzad Aghazadeh each report sole voting power and sole dispositive power over all 5,635,000 shares, with zero shared voting or dispositive power.
  • Beneficial owner of record: According to the filing, Avoro Life Sciences Fund LLC has the right to receive, or the power to direct the receipt of, dividends from or proceeds from the sale of more than 5% of the shares.
  • Investment purpose: The filing certifies the shares "were acquired and are held in the ordinary course of business" and not for the purpose of changing or influencing control of Vera Therapeutics.
  • Triggering event date: The date of the event requiring this filing is stated as September 30, 2026.

Avoro Capital and Aghazadeh Disclose 5,635,000-Share Position in Vera Therapeutics

Avoro Capital Advisors LLC, a Delaware limited liability company, and Behzad Aghazadeh, identified in the filing as the portfolio manager and controlling person of Avoro, jointly filed Amendment No. 2 to Schedule 13G covering their holdings in Vera Therapeutics, Inc. Class A Common Stock (par value $0.001 per share, CUSIP 92337R101). The filing was signed and dated November 16, 2026, with a triggering event date of September 30, 2026. Vera Therapeutics is listed on NASDAQ:VERA.

According to the filing, each reporting person beneficially owns 5,635,000 shares, representing 7.82% of the class. The percentage was calculated using an aggregate of 72,063,335 shares of Class A Common Stock outstanding as of July 29, 2026, as reported in Vera Therapeutics' Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 10, 2026. Each reporting person reports sole voting power and sole dispositive power over all 5,635,000 shares, with no shared voting or dispositive power reported.

The filing states that shares were acquired solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company. The filing further notes that Avoro Life Sciences Fund LLC has the right to receive, or the power to direct the receipt of, dividends from or proceeds from the sale of more than 5% of the Class A Common Stock. The filing includes a certification that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

What Was Disclosed

Avoro Capital Advisors LLC and Behzad Aghazadeh disclosed beneficial ownership of 5,635,000 shares of Vera Therapeutics Class A Common Stock, equaling 7.82% of the class, via Amendment No. 2 to Schedule 13G filed November 16, 2026, covering a September 30, 2026 event date.